EMDR for Health & Longevity - Quick Reference Sheet

EMDR for Health & Longevity

Created on 09/11/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A short course of structured sessions pairs a distressing memory with a repeating left-right task. Evidence is strongest for lasting stress reactions after frightening events and low mood anchored to painful memories, with gains holding for months. Pain and anxiety rest on weaker trials. The eye movements have never been convincingly shown to add anything; harm reporting is nearly absent. (Full Review)

Protocol

Standard eight-phase protocol
8 phases
History and target planning, preparation, assessment, desensitization, installation, body scan, closure, re-evaluation
Typical course length
3 sessions, or 8 to 12
Three for single-incident trauma; 8 to 12 for multiple or childhood trauma. Sessions 60 to 90 minutes, once or twice weekly
Best time of day
Morning or early afternoon
Leaves hours for arousal to settle before sleep; late-evening sessions generally avoided
Time to effect
Single-incident trauma
3 sessions
Often shifts measurably within three reprocessing sessions
Depression
6 to 12 sessions
Typically needed before change is clear
Chronic pain
6 to 12 sessions
Further gains accrue after the course ends

Benefits

Contraindications
  • Acute psychosis or active command hallucinations, until stabilised
  • Recent suicide attempt (within 30 days) or current active suicidal intent without a safety plan
  • Uncontrolled epilepsy or photosensitive seizure disorder, where rapid alternating light stimulation is used
  • Unstable cardiovascular disease, including unstable angina or myocardial infarction (heart attack) within 6 weeks
  • Acute alcohol or sedative withdrawal
  • Severe untreated dissociative disorder, including dissociative identity disorder, without specialist-led extended preparation
Key Interactions
  • Benzodiazepines (sedative anti-anxiety drugs: diazepam, lorazepam, alprazolam, clonazepam): Caution
  • Alcohol and cannabis: Caution
  • Beta-blockers (drugs that blunt the adrenaline response: propranolol, metoprolol): Monitor
  • Opioid analgesics and gabapentinoids (strong painkillers and nerve-pain drugs: morphine, oxycodone, gabapentin, pregabalin): Caution
  • Sedating over-the-counter medication (diphenhydramine, doxylamine, promethazine): Caution
  • Sedating supplements (valerian, kava, high-dose melatonin, cannabidiol): Caution
  • Supplements with additive calming effects (L-Theanine, magnesium glycinate, ashwagandha, glycine): Monitor
  • Stimulants and caffeine: Monitor
  • Other interventions: Monitor (MDMA-assisted therapy, ketamine, psilocybin)

Risk & Side Effects

  • High: Transient distress and emotional arousal; treatment dropout and non-response
  • Medium: Temporary worsening of distress or suicidal thoughts
  • Low: Reduced detail and vividness of targeted memories; dissociative or abreactive reactions
  • Speculative: Blunting of positive emotional memories

Monitoring

Marker Target Why
PCL-5 Below 20, ideally below 11 Tracks the core symptom target
PHQ-9 0 to 4 Catches mood change accompanying reprocessing
SUD rating 0 to 1 at each target's close The in-session signal that a memory has resolved
VOC rating 6 to 7 Confirms the replacement belief has taken hold
DES-II Below 20; 30 or above triggers extended preparation Gauges risk of flooding and loss of dual attention
Resting heart rate 50 to 65 bpm A simple index of sympathetic (fight-or-flight) load
Heart-rate variability (rMSSD) No established target; rising 7-day average vs own baseline Reflects parasympathetic (rest-and-digest) recovery as arousal falls
Blood pressure Below 120/80 mmHg The physical endpoint with the strongest direct trial evidence
hs-CRP Below 1.0 mg/L Body-wide inflammation, plausibly responsive to chronic stress load
Morning DHEA-S to cortisol ratio No established target; track direction vs own baseline The one biochemical marker shown to predict response
Sleep efficiency 85% or above Sleep reflects and plausibly mediates reprocessing gains

Cadence: Distress and belief ratings every session; symptom scales weekly; physical markers at course end, three months and six to twelve months; dissociation screen at intake, repeated only if reactions warrant

Qualitative Assessment

  • Whether the target memory can be brought to mind without a physical reaction
  • Emotional range, meaning access to feelings other than numbness or alarm
  • Startle response to unexpected noise or touch
  • Sleep quality as experienced, and the emotional charge of dreams
  • Cognitive clarity and the effort required to concentrate
  • Avoidance behaviour, meaning places, people and conversations no longer routed around
  • Energy on waking, independent of hours slept